STAT3 Inhibitors SH2 Domain Binding Efficacy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a scarcity of potent, efficacious, and selective inhibitors of STAT3 that are effective in treating diseases associated with STAT3 activity, despite previous developments in phosphopeptide mimics, peptidomimetics, and small molecules, none of which have been FDA-approved.
Innovation Solution
The development of compounds with a specific structure that inhibit STAT3 activity by binding to the STAT3 SH2 domain, including a formula representation, which are used in pharmaceutical compositions and methods for treating STAT-related diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If phosphopeptide mimics and peptidomimetics are used as STAT3 inhibitors, then STAT3 dimerization is inhibited, but the compounds lack sufficient potency and bioavailability for FDA approval
Solution Approach 1:
The patent applies parameter changes by modifying the molecular structure of STAT3 inhibitors through systematic variations in R1, Q1, Q2, Q3, and substituent groups. This allows optimization of key parameters including potency (IC50 values), bioavailability, and selectivity while maintaining the core inhibitory function against STAT3 dimerization
Solution Approach 2:
The patent employs composite molecular structures combining multiple functional groups (aromatic rings, heteroatoms, substituents) into unified inhibitor compounds. These composite structures integrate the benefits of phosphopeptide mimicry with enhanced pharmacological properties, achieving both high potency and improved bioavailability for clinical application
2Ease of operation
If small molecule STAT3 inhibitors are developed, then druggability is improved, but potency and selectivity remain insufficient for clinical use
Solution Approach 1:
The patent applies local quality by designing specific regions within the small molecule inhibitors with distinct functions: the core structure targets the STAT3 SH2 domain for high-affinity binding, while specific substituent groups (R1, Q1, Q2, Q3) provide selectivity and pharmacokinetic optimization. This localized functional differentiation enables both druggability and high selectivity
Solution Approach 2:
The patent utilizes dynamics by creating inhibitors that can adapt their binding mode to the STAT3 SH2 domain. The molecular structures are designed with flexible components that can conformationally adjust to optimize interactions with the target, enhancing both binding affinity and selectivity while maintaining druggability
3Reliability
If existing STAT3 inhibitors are used, then some level of STAT3 phosphorylation inhibition is achieved, but tumor growth suppression and apoptosis induction are insufficient
Solution Approach 1:
The patent applies preliminary action by designing inhibitors that prevent STAT3 phosphorylation and dimerization before these processes can drive tumor growth. By blocking the upstream activation events (phosphorylation at Tyr705 and subsequent dimerization), the compounds preemptively stop the oncogenic signaling cascade, leading to more effective tumor growth suppression and apoptosis induction
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds effectively inhibit STAT3 phosphorylation and dimerization, suppressing tumor growth and inducing apoptosis in cancer cells, as demonstrated by Western blot assays and in vivo mouse tumor models, with improved potency and bioavailability compared to existing inhibitors.
Implementation Method 1
The compounds effectively inhibit STAT3 phosphorylation and dimerization, suppressing tumor growth and inducing apoptosis in cancer cells
Data Source
AI summary
In one aspect, the invention relates to substituted 6-amino-5,8-dioxo-5,8-dihydronaphthalene-1-sulfonamide analogs and derivatives thereof, substituted 4-amino-5H-naphtho[1,8-cd]isothiazol-5-one 1,1-dioxide analogs and derivatives thereof, and related compounds, which are useful as inhibitors of STAT protein activity; synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating disorders of uncontrolled cellular proliferation associated with a STAT protein activity dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.